睿知中国疾病研究地图
候选清单0

正在招募胃癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

ClinicalTrials.gov 上登记的一项胃癌开放试验。牵头方不是本站收录的医院;本站收录的 62 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 62

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心新疆医科大学附属肿瘤医院Affiliated Cancer Hospital of Xinjiang Medical University乌鲁木齐医院页面
  2. 研究中心承德医学院附属医院Affiliated Hospital of Chengde Medical University承德医院页面
  3. 研究中心川北医学院附属医院Affiliated Hospital of North Sichuan Medical College南充医院页面
  4. 研究中心徐州医科大学附属医院Affiliated Hospital of Xuzhou Medical University徐州医院页面
  5. 研究中心安徽省肿瘤医院Anhui Provincial Cancer Hospital合肥医院页面
  6. 研究中心安阳市肿瘤医院Anyang Tumor Hospital安阳医院页面
  7. 研究中心首都医科大学附属北京友谊医院Beijing Friendship Hospital北京医院页面
  8. 研究中心山东第一医科大学附属中心医院(济南市中心医院)Central Hospital Affiliated to Shandong First Medical University济南医院页面
  9. 研究中心吉林大学白求恩第三医院(中日联谊医院)China-Japan Union Hospital, Jilin University长春医院页面
  10. 研究中心重庆医科大学附属第一医院First Affiliated Hospital of Chongqing Medical University重庆医院页面
  11. 研究中心河南科技大学第一附属医院First Affiliated Hospital of Henan University of Science and Technology洛阳医院页面
  12. 研究中心南昌大学第一附属医院First Affiliated Hospital of Nanchang University南昌医院页面
  13. 研究中心苏州大学附属第一医院First Affiliated Hospital of Soochow University苏州医院页面
  14. 研究中心中国科学技术大学附属第一医院(安徽省立医院)First Affiliated Hospital of USTC合肥医院页面
  15. 研究中心西安交通大学第一附属医院First Affiliated Hospital of Xi'an Jiaotong University西安医院页面
  16. 研究中心厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面
  17. 研究中心郑州大学第一附属医院First Affiliated Hospital of Zhengzhou University郑州医院页面
  18. 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
  19. 研究中心中国医科大学附属第一医院First Hospital of China Medical University沈阳医院页面
  20. 研究中心吉林大学第一医院First Hospital of Jilin University长春医院页面
  21. 研究中心兰州大学第一医院First Hospital of Lanzhou University兰州医院页面
  22. 研究中心河北医科大学第四医院Fourth Hospital of Hebei Medical University石家庄医院页面
  23. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面
  24. 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
  25. 研究中心福建医科大学附属协和医院Fujian Medical University Union Hospital福州医院页面
  26. 研究中心福建省立医院Fujian Provincial Hospital福州医院页面
  27. 研究中心甘肃省人民医院Gansu Provincial Hospital兰州医院页面
  28. 研究中心广东省人民医院Guangdong Provincial People's Hospital广州医院页面
  29. 研究中心海南医学院附属医院/海南省人民医院Hainan General Hospital / Hainan Medical University hospitals海口医院页面
  30. 研究中心湖北省肿瘤医院Hubei Cancer Hospital武汉医院页面
  31. 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
  32. 研究中心江苏省肿瘤医院Jiangsu Cancer Hospital南京医院页面
  33. 研究中心江苏省人民医院(南医大一附院)Jiangsu Province Hospital南京医院页面
  34. 研究中心江西省肿瘤医院Jiangxi Cancer Hospital南昌医院页面
  35. 研究中心吉林省肿瘤医院Jilin Cancer Hospital长春医院页面
  36. 研究中心辽宁省肿瘤医院Liaoning Cancer Hospital & Institute沈阳医院页面
  37. 研究中心临沂市肿瘤医院Linyi Cancer Hospital临沂医院页面
  38. 研究中心临沂市人民医院Linyi People's Hospital临沂医院页面
  39. 研究中心南京鼓楼医院Nanjing Drum Tower Hospital南京医院页面
  40. 研究中心江苏省苏北人民医院Northern Jiangsu People's Hospital扬州医院页面
  41. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  42. 研究中心青岛市市立医院Qingdao Municipal Hospital青岛医院页面
  43. 研究中心安徽医科大学第二附属医院Second Affiliated Hospital of Anhui Medical University合肥医院页面
  44. 研究中心浙江大学医学院附属第二医院Second Affiliated Hospital, Zhejiang University杭州医院页面
  45. 研究中心陕西省人民医院Shaanxi Provincial People's Hospital西安医院页面
  46. 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面
  47. 研究中心上海市第一人民医院Shanghai General Hospital上海医院页面
  48. 研究中心汕头大学医学院附属医院Shantou University Medical College hospitals汕头医院页面
  49. 研究中心山西省肿瘤医院Shanxi Cancer Hospital太原医院页面
  50. 研究中心中国医科大学附属盛京医院Shengjing Hospital of China Medical University沈阳医院页面
  51. 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面
  52. 研究中心四川省人民医院Sichuan Provincial People's Hospital成都医院页面
  53. 研究中心浙江大学医学院附属邵逸夫医院Sir Run Run Shaw Hospital杭州医院页面
  54. 研究中心中山大学附属第六医院Sixth Affiliated Hospital of Sun Yat-sen University广州医院页面
  55. 研究中心常州市第一人民医院Third Affiliated Hospital of Soochow University常州医院页面
  56. 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
  57. 研究中心华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面
  58. 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
  59. 研究中心四川大学华西医院West China Hospital成都医院页面
  60. 研究中心空军军医大学西京医院Xijing Hospital西安医院页面
  61. 研究中心云南省肿瘤医院Yunnan Cancer Hospital昆明医院页面
  62. 研究中心复旦大学附属中山医院Zhongshan Hospital, Fudan University上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07385703,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed adenocarcinoma of the stomach or gastroesophageal junction.

    入选标准第 3 条

  3. Patients who have previously received radical neoadjuvant chemotherapy or adjuvant chemotherapy (radiotherapy) based on a platinum-based combination chemotherapy regimen and have not developed distant metastasis or local recurrence within 6 months after completion of treatment can be included.

    入选标准第 5 条

    The calculation of a 6-month interval is defined as recurrence within the same date range after 6 months. For example, if the end date of the last treatment is January 1, the 6-month period from that date refers to January 1 to July 1 (including July 1). Alternatively, if the end date of the last treatment is August 31, the 6-month period from that date refers to August 31 to February 28 (or February 29 in leap years).

    入选标准第 6 条

    Archived specimens or fresh tumor tissue specimens from ≤3 years ago must be provided for CLDN18.2 and PD-L1 testing (PD-L1 results are not a condition for enrollment). When multiple samples are present, the most recent accessible and qualified sample must be provided. After confirmation by the central laboratory, tumor tissue with positive CLDN18.2 expression is defined as ≥25% tumor cell membrane staining intensity 2+ \& 3+. For patients who have previously received radical neoadjuvant chemotherapy or adjuvant chemotherapy (radiotherapy) based on platinum-containing combination chemotherapy regimens, newly obtained tissue from recurrent or metastatic lesions must be provided for CLDN18.2 and PD-L1 testing.

    入选标准第 7 条

    Subjects who received systemic corticosteroids (>10mg/d prednisone equivalent) or other systemic immunosuppressants (including but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor drugs [anti-Tumor Necrosis Factor (TNF)] within 2 weeks prior to the first study drug administration.

    排除标准第 31 条

    Previously received targeted therapy targeting CLDN18.2, such as antibody-drug conjugate (ADC) therapy, antibody therapy, and chimeric antigen receptor T-cell (CAR-T) therapy; previously received ADC therapy using small molecule toxin Monomethyl auristatin E (MMAE).

    排除标准第 41 条

    Subjects who have received palliative local treatment (such as radiotherapy or surgery) for non-target lesions within 2 weeks prior to the first dose, or who have previously received radiotherapy for locally advanced unresectable or metastatic gastric cancer or GEJ adenocarcinoma and have not recovered from toxicity within 2 weeks prior to randomization.

    排除标准第 42 条

    Within the first 2 weeks before randomization, patients received systemic treatment with traditional Chinese patent medicines and simple preparations with anti-tumor indications, or with Chinese herbal medicine, or with drugs with immune regulatory effects (including thymosin, interferon, interleukin, etc.).

    排除标准第 43 条

  4. According to the Eastern Cooperative Oncology Group (ECOG) standards, the physical performance status score is 0 or 1.

    入选标准第 11 条

  5. According to the RECIST 1.1 evaluation criteria, there must be at least one measurable lesion.

    入选标准第 9 条

  6. History of malignancy other than Gastric Cancer (GC)/GastroEsophageal Junction adenocarcinoma (GEJ) adenocarcinoma within 2 years prior to randomization, with the following exceptions: basal cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, squamous cell carcinoma of the skin, etc., which have been completely cured and treated.

    排除标准第 13 条

  7. Women of childbearing age must have a negative blood pregnancy test within 7 days before administration; any fertile male and female subjects must agree to use highly effective contraception throughout the study medication period and for 7 months after the last dose of the study. Males must agree to refrain from donating sperm during the study period and for 7 months after the last dose of the study. Females must agree to refrain from breastfeeding during the study period.

    入选标准第 13 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07385703,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Willing and able to comply with the study's visit schedule, treatment plan, laboratory tests, and other research procedures.
  2. Age ≥ 18 years.
  3. Histologically or cytologically confirmed adenocarcinoma of the stomach or gastroesophageal junction.
  4. For locally advanced unresectable or metastatic adenocarcinoma of the stomach or gastroesophageal junction that has not previously received any systemic treatment:
  5. Patients who have previously received radical neoadjuvant chemotherapy or adjuvant chemotherapy (radiotherapy) based on a platinum-based combination chemotherapy regimen and have not developed distant metastasis or local recurrence within 6 months after completion of treatment can be included.
  6. The calculation of a 6-month interval is defined as recurrence within the same date range after 6 months. For example, if the end date of the last treatment is January 1, the 6-month period from that date refers to January 1 to July 1 (including July 1). Alternatively, if the end date of the last treatment is August 31, the 6-month period from that date refers to August 31 to February 28 (or February 29 in leap years).
  7. Archived specimens or fresh tumor tissue specimens from ≤3 years ago must be provided for CLDN18.2 and PD-L1 testing (PD-L1 results are not a condition for enrollment). When multiple samples are present, the most recent accessible and qualified sample must be provided. After confirmation by the central laboratory, tumor tissue with positive CLDN18.2 expression is defined as ≥25% tumor cell membrane staining intensity 2+ \& 3+. For patients who have previously received radical neoadjuvant chemotherapy or adjuvant chemotherapy (radiotherapy) based on platinum-containing combination chemotherapy regimens, newly obtained tissue from recurrent or metastatic lesions must be provided for CLDN18.2 and PD-L1 testing.
  8. A negative report on the expression detection of human epidermal growth factor receptor-2 (HER2) in tumor tissue must be provided. The definition of HER2 negative expression is ImmunoHistoChemistry (IHC) score 0/1+, IHC score 2+, and fluorescence in situ hybridization (FISH) negative.
  9. According to the RECIST 1.1 evaluation criteria, there must be at least one measurable lesion.
  10. Expected survival duration ≥ 3 months.
  11. According to the Eastern Cooperative Oncology Group (ECOG) standards, the physical performance status score is 0 or 1.
  12. Good organ function: a. Bone marrow reserve: Platelets (PLT) ≥ 100×10\^9/L, absolute neutrophil count (ANC) ≥ 1.5×10\^9/L, Hemoglobin (Hb) ≥ 90 g/L (no blood transfusion or supportive treatment such as colony-stimulating factors within 14 days prior to hematology parameter examination during the screening period); b. Coagulation function: International normalized ratio (INR) ≤ 1.5, Activated partial thromboplastin time (APTT) ≤ 1.5×upper limit of normal (ULN); c. Liver function: Total bilirubin ≤ 1.5×ULN, Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP) ≤ 2.5×ULN (if there is liver metastasis, then ALT and AST ≤ 5×ULN) and Albumin (ALB) ≥ 30 g/L; d. Renal function: Creatinine clearance rate ≥ 50 mL/min (calculated according to the Cockcroft-Gault formula); e. Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 50%; QT interval (QTcF) ≤ 470 ms for females and ≤ 450 ms for males.
  13. Women of childbearing age must have a negative blood pregnancy test within 7 days before administration; any fertile male and female subjects must agree to use highly effective contraception throughout the study medication period and for 7 months after the last dose of the study. Males must agree to refrain from donating sperm during the study period and for 7 months after the last dose of the study. Females must agree to refrain from breastfeeding during the study period.

排除标准:Exclusion Criteria:

  1. Other pathological types confirmed by histopathology, such as squamous cell carcinoma, sarcoma, or undifferentiated carcinoma.
  2. There are gastric cancer lesions confirmed by imaging that are accompanied by cavities or necrosis, and are closely related to major blood vessels, and are assessed by the researchers as posing a high risk of major bleeding.
  3. Patients with known central nervous system (CNS) metastases. Patients with non-meningeal, midbrain, pontine, or spinal cord metastases who are judged by the investigator to have stable brain metastases can be enrolled. Stable brain metastases are defined as patients whose brain metastases have undergone treatment and the condition of the metastases has stabilized (brain imaging examination at least 28 days before randomization shows stable lesions, no neurological symptoms, and no immediate need for local or systemic treatment within 14 days before randomization), with no evidence of new or previously existing brain metastases enlarging.
  4. Clinically uncontrollable third-space effusion, such as moderate or greater volume, requiring long-term catheterization, previous history of intestinal obstruction or paralysis, compartmented ascites, undergoing or planning to undergo local treatment (including drainage, peritoneal shunt, or cell-free concentrated ascites reinfusion therapy) within 14 days prior to screening, or significant increase within 2 weeks after local treatment, meeting any of the above criteria or deemed unsuitable for enrollment by the investigator.
  5. Patients with symptomatic spinal cord compression, or those who are expected to develop symptoms of spinal cord compression if left untreated; or for patients with previously diagnosed and treated spinal cord compression, there is no evidence indicating that the disease was clinically stable for ≥4 weeks before the first study drug administration; except for patients with asymptomatic spinal cord compression indicated by imaging, who are assessed as stable by a specialist and do not require treatment for spinal cord compression at this time.
  6. Accompanied by severe peritoneal metastasis, the main manifestations are: clinically significant intestinal obstruction; barium enema indicating small intestinal stenosis.
  7. History of gastrointestinal perforation or gastrointestinal fistula within the previous 6 months. If the perforation or fistula has been treated through resection or repair surgery, and the condition is assessed by the investigator as having been cured or controlled, participation in the study is permissible.
  8. Poorly controlled tumor-related pain:
  9. For patients requiring analgesic treatment, a stable dosage of treatment must be established before participating in the study.
  10. Symptomatic lesions suitable for palliative radiotherapy (such as bone metastasis or metastasis causing nerve damage) should be treated before enrollment.
  11. Before enrollment, if appropriate, consideration should be given to local treatment for asymptomatic metastatic lesions that may lead to functional deficits or intractable pain due to further growth (e.g., epidural metastasis not currently associated with spinal cord compression).
  12. Patients with a body weight of less than 35kg or a body weight loss of more than 10% within 2 months prior to signing the informed consent form.
  13. History of malignancy other than Gastric Cancer (GC)/GastroEsophageal Junction adenocarcinoma (GEJ) adenocarcinoma within 2 years prior to randomization, with the following exceptions: basal cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, squamous cell carcinoma of the skin, etc., which have been completely cured and treated.
  14. History of autoimmune diseases, including but not limited to: myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. The following conditions are excluded: • Subjects with autoimmune-related hypothyroidism who are receiving stable-dose thyroid hormone replacement therapy.
  15. Subjects with type 1 diabetes who are well-controlled under a stable insulin treatment regimen.
  16. Only subjects with skin autoimmune diseases that do not require systemic treatment (such as vitiligo, alopecia, psoriasis, or eczema).
  17. Subjects who have recovered from childhood asthma and do not require any intervention in adulthood.
  18. Subjects whose relevant diseases, as assessed by the researchers, are unlikely to recur without external triggers.
  19. Patients who have previously undergone allogeneic bone marrow transplantation or solid organ transplantation.
  20. Patients with a history of severe cardiovascular and cerebrovascular diseases, including but not limited to:
  21. Severe cardiac rhythm or conduction abnormalities, such as arrhythmias requiring clinical intervention, second- or third-degree atrioventricular block, left bundle branch block, prolonged QRS complex, etc.;
  22. Patients with thromboembolic events requiring therapeutic anticoagulation, or those with venous filters;
  23. Patients with heart failure of New York Heart Association (NYHA) class III or IV;
  24. Patients who have experienced acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other cardiovascular and cerebrovascular events of grade 3 or above within the previous 6 months prior to randomization.
  25. Have a history of myocarditis or cardiomyopathy.
  26. For individuals infected with human immunodeficiency virus (HIV) and those with active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, the following conditions are allowed for enrollment: • Patients who are HBsAg positive, with or without HBcAb positivity, and have HBV DNA < 500 IU/mL or below the lower limit of the reference value set by the research center, and who, based on clinical treatment, manifestations, and other factors, are judged by the investigator to have no active infection; • Patients who are HCV antibody positive but HCV RNA negative.
  27. Subjects with known active syphilis infection.
  28. Individuals who are unable to control themselves or have severe illnesses, including but not limited to active infections requiring systemic antibiotic treatment within 2 weeks before the first dose, and interstitial pneumonia/lung disease requiring intervention during screening.
  29. Subjects with known active tuberculosis. For patients suspected of having active tuberculosis, a comprehensive evaluation should be conducted based on chest imaging, sputum smear/culture, or molecular testing results, as well as clinical symptoms and signs, to make a definitive diagnosis.
  30. Currently present peripheral sensory or motor neuropathy of ≥ grade 2.
  31. Subjects who received systemic corticosteroids (>10mg/d prednisone equivalent) or other systemic immunosuppressants (including but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor drugs [anti-Tumor Necrosis Factor (TNF)] within 2 weeks prior to the first study drug administration.
  32. Topical, ocular, intra-articular, intranasal, and inhaled corticosteroids are allowed;
  33. Patients receiving acute low-dose systemic immunosuppressive drugs (e.g., single-dose dexamethasone for nausea);
  34. Patients requiring baseline and subsequent MRI/CT tumor assessments who have previously experienced allergic reactions to intravenous contrast agents may receive prophylactic steroids;
  35. Inhaled corticosteroids are allowed for the treatment of chronic obstructive pulmonary disease, hydrocortisone for the treatment of orthostatic hypotension, and low-dose corticosteroid hormone maintenance therapy for adrenal insufficiency.
  36. There are factors that affect the application and absorption of oral medications, such as dysphagia, clinically uncontrollable persistent and recurrent vomiting (such as caused by gastric outlet obstruction), intestinal obstruction, and chronic diarrhea. 21. Within 28 days before randomization, there was uncontrollable/severe gastrointestinal bleeding, active peptic ulcer, or active gastrointestinal inflammation/infectious diseases (such as active diverticulitis, abdominal abscess). Subjects who have not undergone radical surgical resection of the primary lesion must undergo fecal occult blood testing before enrollment. If the result is positive, further evaluation, including but not limited to gastroscopy, is required before medication administration to confirm the presence of active bleeding from the lesion and assess the risk of bleeding.
  37. The adverse reactions from previous anti-tumor treatment within the 14 days prior to randomization have not yet recovered to a level of ≤ grade 1 according to the Common Terminology Criteria for Adverse Events (CTCAE) v6.0 grading system (excluding toxicities that the investigator deems to pose no safety risk, are asymptomatic, or are controllable with stable medication, such as hair loss, long-term toxicity caused by radiotherapy, and other toxicities that are ≤ grade 2).
  38. Have a history of allergy to LM-302, Ticagrelor, any control drug, or its excipients.
  39. Individuals with known mental illnesses or disorders that may affect trial compliance.
  40. Within 28 days prior to randomization, the subject is currently participating or has previously participated in any investigational drug study, or has used an investigational device within 28 days. Subjects who have entered the follow-up period of an investigational drug study and have not used the investigational drug for ≥28 days since the last use may meet the inclusion criteria for this study.
  41. Previously received targeted therapy targeting CLDN18.2, such as antibody-drug conjugate (ADC) therapy, antibody therapy, and chimeric antigen receptor T-cell (CAR-T) therapy; previously received ADC therapy using small molecule toxin Monomethyl auristatin E (MMAE).
  42. Subjects who have received palliative local treatment (such as radiotherapy or surgery) for non-target lesions within 2 weeks prior to the first dose, or who have previously received radiotherapy for locally advanced unresectable or metastatic gastric cancer or GEJ adenocarcinoma and have not recovered from toxicity within 2 weeks prior to randomization.
  43. Within the first 2 weeks before randomization, patients received systemic treatment with traditional Chinese patent medicines and simple preparations with anti-tumor indications, or with Chinese herbal medicine, or with drugs with immune regulatory effects (including thymosin, interferon, interleukin, etc.).
  44. Having undergone or planning to undergo major surgery or interventional therapy (excluding tumor biopsy, puncture, etc.) within the 28 days prior to randomization or during the study period.
  45. Use of strong inhibitors/strong inducers of CYP3A4 within 14 days before randomization;
  46. Vaccination with any live vaccine or attenuated live vaccine within 28 days before randomization.
  47. Other situations where the researcher deems it inappropriate for participation in this study.

引自 ClinicalTrials.gov, NCT07385703, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07385703,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07385703